MEDI Medimmune (MM)

0.00

0.00 (0.00%)

- - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Medimmune (MM)	NASDAQ:MEDI	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%							0	-

MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Di

08/05/2007 6:01pm

PR Newswire (US)

Medimmune (NASDAQ:MEDI)
Historical Stock Chart

From Jun 2019 to Jun 2024

- Numax Achieves Primary Endpoint Among High-Risk Infants Versus Current Standard of Care and Shows Reduction of Medically Attended Outpatient RSV- Related Lower Respiratory Infections - TORONTO, May 8 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced positive results from a large prospective trial conducted for prevention of respiratory syncytial virus (RSV). The trial compared motavizumab, the investigational monoclonal antibody (MAb) also known as Numax(R), with Synagis(R) (palivizumab), the standard of care for preventing RSV hospitalization in high-risk infants. In the Phase 3 study involving 6,635 pre-term infants at high risk for RSV, with a primary endpoint of non- inferiority, motavizumab demonstrated overall 26-percent fewer RSV hospitalizations compared with Synagis (p